Mutant p53 acts as a strong dominant-negative inhibitor against p53 family members; however, RUNX2 depletion-mediated up-regulation of TAp73 and/or TAp63 resulted in an increase in GEM sensitivity of p53-mutated pancreatic cancer cells, which might be at least in part due to the disruption of the intracellular balance between the amounts of mutant p53 and TAp73/TAp63. Here, TP53 is linked to pancreatic neoplasm.